Vacuna BCG SSI (Instituto Statens de vacunas) / BCG vaccine statens serum intitut

Vacuna BCG  SSI (Instituto Statens de vacunas) / BCG vaccine statens serum intitut

Danish strain 1331 / Cepa danesa  1331

GUÍA PARA INMUNIZACIÓN CONTRA LA TUBERCULOSIS

En general es aceptado que el mejor método para la vacunación con BCG  es con aguja vía intradérmica. Este es el método más exacto pues la dosis puede ser medida con mayor precisión, y su administración es controlada. Lo cual minimiza las reacciones adversas.

La vacuna multidosis es un liofilizado que se conserva refrigerado a temperaturas entre 2 y 8 oC, se reconstituye para la aplicación y se descarta a las 4 horas máximo.

La vacuna deja marca (cicatriz) que aparece a los pocos días, al momento de la vacunación puede quedar en piel una pequeña ampolla, parecida a la picadura de un mosquito, en el sitio de la inoculación que cede a los pocos minutos.

Su indicación es para disminuir la posibilidad de padecer tuberculosis y evitar las tuberculosis complicadas como la generalizada y la cerebral.

Información extraída del prospecto de la vacuna.

Alejandro Rísquez

Nicole Ritz, Nigel Curtis. Tuberculosis - July 2009 (Vol. 89, Issue 4, Pages 248-251, DOI: 10.1016/j.tube.2009.03.002)

Mapping the global use of different BCG vaccine strains

Principio del formulario

·         Nicole Ritz

·         Tuberculosis
Volume 89, Issue 4 , Pages 248-251, July 2009

, 

·         Nigel Curtis

Final del formulario

Received 3 February 2009; received in revised form 24 February 2009; accepted 23 March 2009. published online 19 June 2009.

·         Abstract

·         Full Text

·         PDF

·         Images

·         References

Summary 

Bacille Calmette–Guérin (BCG) vaccine is one of the oldest and most commonly administered vaccines worldwide. Different BCG vaccine strains exist as a result of genetic changes that occurred during repeated subculture in different countries before lyophilisation was introduced for storage of seed lots in the 1960s. Increasing evidence suggests that these genetically divergent BCG vaccine strains are associated with different protective efficacy against tuberculosis (TB), different rates of adverse events and variable susceptibility to anti-tuberculous drugs. Information on which BCG vaccine strains are used in each country worldwide has not previously been collated. This report summarises data from the EuroTB network and from WHO/UNICEF in the first map depicting the BCG vaccine strains used globally. In 83 (44%) of 188 countries, more than one BCG vaccine strain was used during the five year period. In the countries that used only one strain, BCG Denmark was used in 32, BCG Russia/Bulgaria in 30, BCG Japan in eight, BCG Connaught in two. Twelve countries used their locally-produced BCG vaccine strains. The considerable variation in BCG vaccine strains used worldwide highlights the importance of documenting the particular vaccine strain used on an individual, local and national level. This is important for the interpretation of changes in the epidemiology of adverse events after BCG immunisation, for the management of adverse events after BCG immunisation, to interpret differences in the protective efficacy of BCG, and to inform the design of trials investigating novel TB vaccines.

Keywords: BCG, Strain, Vaccine, Map, Immunisation